advanced search
2023 June Inhalation HW Boston

ten23 health

ten23 health develops, manufactures and tests products for the pharmaceutical industry and biotech start-ups. ten23 health supports its clients in developing differentiated, stable, usable and safe injectable treatment options for patients. swissfillon is a wholly owned subsidiary.


Visit Website

Headquarters
ten23 health AG
Mattenstrasse 22
4058 Basel
Switzerland

Phone / Contact

E: contact@ten23.health

Connect

ten23 health is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: the company develops, manufactures and tests tomorrow’s medicines. ten23 health supports its clients in developing differentiated, stable, usable and safe injectable treatment options for patients.

swissfillon, a leader in the sterile filling of complex pharmaceuticals into innovative containers and devices, and based in Visp, Switzerland, is a wholly owned subsidiary.

Regarding the company’s name: the numeric value for the number of molecules in a sample of 1 mol is called Avogradro’s constant and equals 6.022 x 1023. Gramme quantities of material contain the incredible number of 1023 atoms, which was an important discovery in the understanding of the composition of matter: the world is built from small units and
not a homogeneous mass.

 

0

SHARE

Articles by ten23 health

INDUSTRIALISATION
Dr Andrea Allmendinger
INTEGRATED DRUG PRODUCT DEVELOPMENT AND MANUFACTURING
Andrea Allmendinger; Michael Adler and Hanns-Christian Mahler highlight the importance of integrated drug product development, considering aspects such as formulation, device, container closure system, manufacturing processes and usability, as well as considering the quality target product profile and clinical phase-appropriate technical development strategy.
OCULAR
Dr Andrea Allmendinger
INTRAVITREAL INJECTIONS – MORE THAN MEETS THE EYE: A TECHNICAL VIEW OF PRODUCT USE
Andrea Allmendinger and Hanns-Christian Mahler highlight the technical challenges of intravitreal administration and considerations from the ophthalmologist’s and patient’s perspectives.
PREFILLED SYRINGES
Dr Andrea Allmendinger
ANTICIPATING & MITIGATING CHALLENGES IN THE COMMERCIALISATION OF PREFILLED SYRINGES & INJECTION DEVICES – A TECHNICAL DRUG PRODUCT PERSPECTIVE
Andrea Allmendinger and Hanns-Christian Mahler both at ten23 health, provide an insight into the challenges of integrated development of drug product and device design and fill-finish manufacturing operations.
OCULAR
Dr Andrea Allmendinger
HOW TEN23 HEALTH IS MEETING DEVELOPMENTAL CHALLENGES FOR INTRAVITREAL PRODUCTS
Andrea Allmendinger and Hanns-Christian Mahler highlight new regulatory and quality requirements for intravitreal applications and discuss technical challenges during drug product technical development and manufacturing.
OCULAR
Rainer Glockler
OPHTHALMIC DRUGS: PATHWAY TO OVERCOME PRIMARY PACKAGING AND DRUG PRODUCT MANUFACTURING CHALLENGES
Rainer Glöckler, Carole Delauney, Dr Nicolas Eon and Katsuyuki Takeuchi discuss the myriad complexities of developing drug products for intravitreal injection, and how the partnership between swissfillon and Terumo can ease and accelerate these products to market. The first article, published in April, covered how swissfillon’s state-of-the-art filling line meets the complex requirements of ophthalmic drug products.
OCULAR
Rainer Glockler
STATE-OF-THE-ART SOLUTIONS FOR OPHTHALMIC STERILE DRUG PRODUCT MANUFACTURING
In the first in a series of two articles, Rainer Glöckler and Carole Delauney discuss how the company’s state-of-the-art filling line meets the requirements and complexities that are particular to ophthalmic drug product manufacturing. The second article, to be published in May, will explore partnerships between pharma, CDMOs and syringe manufacturers in more detail.
Top